Wells Fargo’s PharmaCyte Biotech PMCB Stock Holding History

Wells Fargo’s Portfolio PMCB Stock Details PMCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-55	Closed	-$130	–	7329
2024 Q1	$130	Hold	55	–	–	﹤0.01%	6599
2023 Q4	$119	Buy	55 +2	+4%	+$4	﹤0.01%	6722
2023 Q3	$111	Sell	53 -132	-71%	-$337	﹤0.01%	6743
2023 Q2	$529	Buy	185 +56	+43%	+$168	﹤0.01%	6477
2023 Q1	$375	Sell	129 -12	-9%	-$35	﹤0.01%	6617
2022 Q4	$413	Buy	141 +3	+2%	+$9	﹤0.01%	6435
2022 Q3	$0	Sell	138 -1	-0.7%	-$3	﹤0.01%	7191
2022 Q2	$0	Buy	139 +11	+9%	+$24	﹤0.01%	7316
2022 Q1	$0	Buy	128 +1	+0.8%	+$2	﹤0.01%	7629
2021 Q4	$0	Buy	127 +101	+388%	+$278	﹤0.01%	7663
2021 Q3	$0	Buy	+26	New	+$91	﹤0.01%	7376

Other funds holding PMCB

KPF

K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EPM

Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Wells Fargo's PMCB Position: Q2 2024 in Review

Wells Fargo sold out of PharmaCyte Biotech (PMCB) in Q2 2024, closing a stake of 55 shares — an estimated $130 sold.

Wells Fargo first reported a position in PMCB in Q3 2021 and held it in 11 quarters. The position peaked at $529 in Q2 2023. 28 funds tracked by Wall St. Rank hold PMCB as of Q2 2024.

Wells Fargo reported no remaining PharmaCyte Biotech position as of Q2 2024 after selling out during the quarter.
Wells Fargo sold 55 PharmaCyte Biotech shares in Q2 2024, an estimated $130.
Wells Fargo first reported a position in PharmaCyte Biotech in Q3 2021 and held it in 11 quarters.
Wells Fargo's PharmaCyte Biotech position peaked at $529 in Q2 2023.
28 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q2 2024.

Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.